Bicycle has a wobble
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
Triple meeting 2024 – Aktis radiotherapy heads for the clinic
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
Ipsen casts doubt on Pfizer’s prostate plan
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
